← Eichor
Condition: Xerostomia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Xerostomia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Effects of Transcutaneous Vagus Nerve Stimulation in Parkinson´s Disease
NA · 1 location(s) · Universidade da Coruña · NCT07588191Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Diseas
Phase N/A · 1 location(s) · Hospital Universitario Araba · NCT07249060The Pathogenesis and Natural History of Sjogren's Disease
Phase N/A · 1 location(s) · National Institute of Dental and Craniofacial Research (NIDC · NCT01425892Belimumab After Rituximab in Resistant Primary Juvenile SS
Phase 4 · 1 location(s) · Peking Union Medical College Hospital · NCT06410833Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Nanjing Bioheng Biotech Co., Ltd. · NCT06548607Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study
NA · 1 location(s) · Universidad de Granada · NCT05106608Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1
Phase 1/Phase 2 · 4 location(s) · RiboX Therapeutics Ltd. · NCT06714253Ultra-High Frequency Ultrasonography in Sjögren's Syndrome
NA · 1 location(s) · University of Pisa · NCT06338735An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
NA · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT06379646A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Phase 3 · 174 location(s) · Amgen · NCT06747949Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
Phase 2 · 1 location(s) · National Institute of Dental and Craniofacial Research (NIDC · NCT07281456Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT
Phase 1/Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07062523Fatigue in Sjögren's Syndrome: 3 Therapeutic Strategies
NA · 1 location(s) · Centre Hospitalier Universitaire de Saint Etienne · NCT06875102Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders
NA · 1 location(s) · Terry L. Wahls · NCT07180537Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06056921Functional Analysis of Salivary Glands and Correlation With Sialoscintigraphy in Sjogren's Syndrome
NA · 1 location(s) · National Taiwan University Hospital · NCT06536075A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Phase 1 · 19 location(s) · GlaxoSmithKline · NCT07371468The Effects of Using Augmented Reality (AR) System to Train Foreign Care Workers.
NA · 1 location(s) · Kaohsiung Medical University Chung-Ho Memorial Hospital · NCT05938166Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With S
Phase 3 · 2 location(s) · Novartis Pharmaceuticals · NCT07621809The Myelin Disorders Biorepository Project
Phase N/A · 23 location(s) · Children's Hospital of Philadelphia · NCT03047369Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT07361094Application of Neuro-electrostimulation as a Treatment for Patients With Dry Mouth
NA · 1 location(s) · Universidad Autonoma del Estado de Mexico · NCT07593495Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
Phase 1 · 1 location(s) · University of Wisconsin, Madison · NCT06392711A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
Phase 1 · 11 location(s) · Cullinan Therapeutics Inc. · NCT07041099Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Phase 3 · 28 location(s) · Vor Biopharma · NCT07404865Acupressure on Xerostomia in Head and Neck Cancer Patients
NA · 1 location(s) · The University of Hong Kong · NCT06465628Effect of Enzymatic-Containing Mouth Spray (Oral7®) on Xerostomia Symptoms, Salivary Flow Rate, and Oral Health-Related
NA · 1 location(s) · ZAINAB MAT YUDIN · NCT06984848New Clinical End-points in Patients With Primary Sjögren's Syndrome
Phase 2 · 7 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05113004Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Sy
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT05927688MTS109 in Patients With Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Shanghai Changzheng Hospital · NCT07526350
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.